Global Blood Therapeutics, Inc. (NASDAQ:GBT) Forecasted to Post FY2022 Earnings of ($4.55) Per Share
Global Blood Therapeutics, Inc. (NASDAQ:GBT) Forecasted to Post FY2022 Earnings of ($4.55) Per Share
Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for shares of Global Blood Therapeutics in a research note issued to investors on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings per share of ($4.55) for the year. Cantor Fitzgerald has a "Neutral" rating on the stock. The consensus estimate for Global Blood Therapeutics' current full-year earnings is ($4.71) per share. Cantor Fitzgerald also issued estimates for Global Blood Therapeutics' FY2023 earnings at ($3.03) EPS.
全球血液治療學公司（NASDAQ：GBT-獲取評級）— 坎特·菲茨杰拉德的研究分析師在 9 月 21 日（週三）發布給投資者的研究報告中發布了全球血液治療學股份的 FY2022 盈利估計。坎特·菲茨杰拉德分析師 L· 瓦塞克預計，該公司將張貼每股收益（4.55 美元）年度。坎特·菲茨杰拉德對股票有「中性」的評級。全球血液治療當前全年收益的共識估計為每股（4.71 美元）。坎特·菲茨杰拉德還發布了全球血液治療 FY2023 盈利（3.03 美元）每股收益的估計值。
GBT has been the subject of several other research reports. Cowen lowered shares of Global Blood Therapeutics to a "market perform" rating and boosted their price target for the company from $67.00 to $68.50 in a report on Tuesday, August 9th. Guggenheim boosted their price target on shares of Global Blood Therapeutics to $72.00 in a report on Monday, August 15th. Canaccord Genuity Group upgraded shares of Global Blood Therapeutics from a "hold" rating to a "buy" rating and boosted their price target for the company from $40.00 to $72.00 in a report on Monday, August 8th. Oppenheimer lowered shares of Global Blood Therapeutics to a "market perform" rating in a report on Monday, August 15th. Finally, Wedbush downgraded shares of Global Blood Therapeutics to a "neutral" rating in a research report on Monday, August 15th. Twelve research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $65.50.
GBT 一直是其他幾個研究報告的主題。科恩將全球血液治療學的股票降至「市場表現」評級，並將公司的目標價格從 67.00 美元提高到 68.50 美元（週二），8 月 9 日。在 8 月 15 日星期一的報告中，古根海姆將全球血液治療學股票的價格目標提高至 72.00 美元。Canaccord Genuity 集團將全球血液治療的股票從「持有」評級升級為「買入」評級，並在 8 月 8 日星期一的報告中將該公司的目標價格從 40.00 美元提高到 72.00 美元。奧本海默在 8 月 15 日星期一的報告中將全球血液治療學的份額降低到「市場表現」評級。最後，在 8 月 15 日星期一的研究報告中，Wedbush 將全球血液治療學的份額降級為「中性」評級。十二位研究分析師對該股票進行了保持評級，五名分析師對該公司分配了買入評級。根據來自 MarketBeat.com 的數據，該股票目前的平均評級為「持有」，共識目標價為 65.50 美元。
Global Blood Therapeutics Trading Up 0.0 %
全球血液療法交易上升 0.0%
Global Blood Therapeutics (NASDAQ:GBT – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.07). Global Blood Therapeutics had a negative net margin of 137.30% and a negative return on equity of 170.37%. The company had revenue of $71.55 million for the quarter, compared to the consensus estimate of $64.39 million. During the same quarter in the previous year, the business earned ($1.12) EPS.
全球血液治療學（NASDAQ：GBT-獲取評級）上次公佈了其季度收益數據，週一，8 月 8 日。該公司報告了本季度每股盈利（1.26 美元），缺失分析師的共識估計為（1.19 美元）（0.07 美元）。全球血液治療的負淨利潤率為 137.30％，負資產回報率為 170.37%。該公司本季度的收入為 71.55 萬美元，而共識估計為 6439 億美元。在上一年的同一季度，該業務每股盈利（1.12 美元）。
Insiders Place Their Bets
內部人士下注
In other Global Blood Therapeutics news, insider Nazila Habibizad sold 4,678 shares of the business's stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $67.19, for a total transaction of $314,314.82. Following the sale, the insider now owns 8,918 shares of the company's stock, valued at approximately $599,200.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.90% of the stock is owned by insiders.
在其他全球血液治療新聞中，內幕納茲拉·哈比比扎德（Nazila Habibizad）在 8 月 18 日（星期四）進行的交易中出售了該業務股票的 4,678 股。這些股份以 67.19 美元的平均價格出售，總交易額為 314,314.82 美元。出售後，內幕人士現在擁有該公司股票的 8,918 股，價值約為 599,200.42 美元。該交易在與 SEC 合法提交的文件中披露，可通過以下方式訪問 證券交易所網站4.90％ 的股票由內部人士擁有。
Institutional Trading of Global Blood Therapeutics
全球血液治療的機構交易
Large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its holdings in shares of Global Blood Therapeutics by 75.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company's stock valued at $52,000 after acquiring an additional 650 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Global Blood Therapeutics in the 1st quarter valued at $448,000. Candriam Luxembourg S.C.A. lifted its stake in shares of Global Blood Therapeutics by 16.7% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 756,708 shares of the company's stock valued at $26,211,000 after purchasing an additional 108,369 shares during the period. Fairmount Funds Management LLC lifted its stake in shares of Global Blood Therapeutics by 59.1% in the 1st quarter. Fairmount Funds Management LLC now owns 1,182,307 shares of the company's stock valued at $40,955,000 after purchasing an additional 439,307 shares during the period. Finally, Vestmark Advisory Solutions Inc. lifted its stake in shares of Global Blood Therapeutics by 44.3% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 12,669 shares of the company's stock valued at $439,000 after purchasing an additional 3,892 shares during the period.
大型投資者最近更改了他們在業務中的位置。Nisa 投資顧問有限責任公司在第一季度將其在全球血液治療的佔有率提高了 75.6％。Nisa 投資顧問有限責任公司現在擁有該公司 1,510 股，價值為 52,000 美元的股票，在上一個季度額外收購 650 股後。坎貝爾 ＆CO 投資顧問有限責任公司在第一季度收購了全球血液治療學股份的新職位，價值為 448,000 美元。坎德里亞姆盧森堡 S.C.A. 在第一季度將其全球血液治療學股份的股份提升了 16.7％。康德瑞姆盧森堡股份有限公司現在擁有該公司 756,708 股股份，價值 26,211,000 美元，於期內另外購買 108,369 股股份後。費爾蒙基金管理有限責任公司在第一季度將其全球血液治療學股份的股份提升了 59.1％。費爾蒙基金管理有限責任公司現在擁有該公司股票的 1,182,307 股股份，價值為 40,955,000 美元，在此期間額外購買 439,307 股。最後，Vestmark 諮詢解決方案公司在第一季度將其在全球血液治療學股份的股份上升了 44.3％。維斯特馬克諮詢解決方案公司現在擁有該公司股票的 12,669 股，價值為 439,000 美元，在此期間額外購買 3,892 股後。
Global Blood Therapeutics Company Profile
全球血液治療公司簡介
(Get Rating)
(取得評分)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
Global Plood Theraptics, Inc. 是一家生物製藥公司，致力於為鐮狀細胞病（SCD）服務不足的患者群體的發現，開發和提供治療。該公司提供 Oxbryta 片劑，這是一種口服的 SCD 每日一次治療。它還評估了 SCD 青少年和兒科患者的 II 期單劑和多劑 Oxbryta 的安全性和藥代動力學。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 獲取有關全球血液治療研究報告的免費副本
- 市場節拍：評論中的一周 9/19 — 9 月 23 日
- 為什麼特斯拉股票保持彈性？
- 2 個半導體股票需要注意反轉
- 好市多的收益後價格疲軟是買入的好時機嗎？
- 群眾罷工會從增加 EPS 指南中獲得提升嗎？
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收全球血液治療日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關全球血液治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。